AbbVie Inc. and Amgen Inc. have settled litigation surrounding the latter's intellectual property related to a proposed biosimilar adalimumab named AmgevitaAmjevita. Under the settlement Amgen receives a nonexclusive global license to AbbVie's Humirarelate...
↧